More on AGMB
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $9.11 |
|
|||
| Open | $9.15 | ||||
| 52 Wk High | $0.01 | ||||
| 52 Wk Low | $0.01 | ||||
| Day High | $9.44 | ||||
| Day Low | $8.90 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 84,322 | ||||
- Form 4 AgomAb Therapeutics NV For: Oct 21 Filed by: Epstein David R
- H.C. Wainwright Reiterates Buy Rating on Agomab Therapeutics (AGMB)
- Form 6-K AgomAb Therapeutics NV For: Oct 13
- Agomab doses first patient in Phase 2b Crohn's disease study
- Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
- Form 4 AgomAb Therapeutics NV For: Oct 08 Filed by: Epstein David R
- Form 4 AgomAb Therapeutics NV For: Oct 05 Filed by: Epstein David R
- Form 4 AgomAb Therapeutics NV For: Oct 06 Filed by: Kemula Pierre Thadee Victor
- Form 4 AgomAb Therapeutics NV For: Oct 05 Filed by: Knotnerus Tim Jasper
- H.C. Wainwright Reiterates Buy Rating on Agomab Therapeutics (AGMB)
Entities mentioned with AGMB
- IPO | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- FDA | View Related Stories »
- JPMorgan | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Morgan Stanley | View Related Stories »
- Show More...
